OTCMKTS:NVLNF Novelion Therapeutics (NVLNF) Stock Price, News & Analysis → The Department of Defense Has a New Drone Contractor (From The Tomorrow Investor) (Ad) Free NVLNF Stock Alerts $0.70 -0.01 (-1.20%) (As of 01/16/2020) Add Compare Share Share Today's Range$0.70▼$0.7550-Day Range$0.70▼$0.7052-Week Range$0.51▼$1.00Volume26,900 shsAverage Volume261,364 shsMarket Capitalization$13.77 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Novelion Therapeutics alerts: Email Address Ad Porter & CompanyHow Biden has already won 2024Obama’s Forever Term [Exposed] or Obama Biden has already won 2024 Exposed: the shocking election plot that will forever enshrine Obama’s destructive, Marxist vision for America… A plot that could hand him and his allies near-total control over the government, your way of life, and your future.Click here to watch this now before it’s too late. About Novelion TherapeuticsNovelion Therapeutics Inc., a biopharmaceutical company, develops therapies for individuals living with rare diseases in the United States, Japan, Brazil, and internationally. Its commercial products include metreleptin, a recombinant analog of human leptin, which is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy under the MYALEPTA brand name; and lomitapide capsule for the treatment of adult patients with homozygous familial hypercholesterolemia under the JUXTAPID and LOJUXTA brands. The company was formerly known as QLT Inc. and changed its name to Novelion Therapeutics Inc. in November 2016. Novelion Therapeutics Inc. was founded in 1981 and is headquartered in Vancouver, Canada.Read More NVLNF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NVLNF Stock News HeadlinesNo headlines for this company have been tracked by MarketBeat.com Receive NVLNF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Novelion Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolOTCMKTS:NVLNF CUSIPN/A CIKN/A Webwww.novelion.com Phone617-500-7867FaxN/AEmployees109Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$130.43 million Price / Sales0.11 Cash FlowN/A Price / Cash FlowN/A Book Value($4.69) per share Price / Book-0.15Miscellaneous Outstanding Shares19,619,000Free FloatN/AMarket Cap$13.77 million OptionableNot Optionable Beta2.15 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Benjamin S. Harshbarger (Age 50)Interim CEO, Gen. Counsel & Corp. Sec. Mr. Michael D. Price (Age 61)Exec. VP, CFO & Director Ms. Barbara Y. Chan (Age 55)VP & Chief Accounting Officer Ms. Amanda MurphyDirector of Investor Relations & Corp. CommunicationsMs. Linda Buono (Age 53)Sr. VP of HR Key CompetitorsPieris PharmaceuticalsNASDAQ:PIRSFSD PharmaNASDAQ:HUGERedHill BiopharmaNASDAQ:RDHLPurple BiotechNASDAQ:PPBTCeaproOTCMKTS:CRPOFView All Competitors NVLNF Stock Analysis - Frequently Asked Questions How have NVLNF shares performed in 2024? Novelion Therapeutics' stock was trading at $0.7020 on January 1st, 2024. Since then, NVLNF shares have increased by 0.0% and is now trading at $0.7020. View the best growth stocks for 2024 here. How do I buy shares of Novelion Therapeutics? Shares of NVLNF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:NVLNF) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe Crypto 9-5 Escape PlanCrypto 101 MediaThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsCharles Payne Demystifies OptionsUnstoppable ProsperityTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novelion Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.